Functional Sympatholysis During Exercise in Patients With Type 2 Diabetes With Intact Response to Acetylcholine by Thaning, Pia et al.
Functional Sympatholysis During
ExerciseinPatientsWithType2Diabetes
With Intact Response to Acetylcholine
PIA THANING, MD
1,2
LAURIDS T. BUNE, MD
1
MORTEN ZAAR, MSC
1
BENGT SALTIN, DRMED
1
JAYA B. ROSENMEIER, PHD
1,3
OBJECTIVE—Sympatheticvasoconstrictionisbluntedincontractinghumanskeletalmuscles
(functional sympatholysis). In young subjects, infusion of adenosine and ATP increases blood
ﬂow, and the latter compound also attenuates a-adrenergic vasoconstriction. In patients with
type2diabetesandage-matchedhealthysubjects,wetested1)thesympatholyticcapacityduring
one-leggedexercise,2)thevasodilatorycapacityofadenosineandATP,and3)theabilitytoblunt
a-adrenergic vasoconstriction during ATP infusion.
RESEARCH DESIGN AND METHODS—In 10 control subjects and 10 patients with
diabetes and normal endothelial function, determined by leg blood ﬂow (LBF) response to
acetylcholine infusion, we measured LBF and venous NA, with and without tyramine-induced
sympathetic vasoconstriction, during adenosine-, ATP-, and exercise-induced hyperemia.
RESULTS—LBF during acetylcholine did not differ signiﬁcantly. LBF increased ninefold dur-
ing exercise and during adenosine- and ATP-induced hyperemia. Infusion of tyramine during
exercisedidnotreduceLBFineitherthecontrolor thepatientgroup.DuringcombinedATPand
tyramine infusions, LBF decreased by 30% in both groups. Adenosine had no sympatholytic
effect.
CONCLUSIONS—In patients with type 2 diabetes and normal endothelial function, func-
tional sympatholysis was intact during moderate exercise. The vasodilatory response for aden-
osine and ATP did not differ between the patients with diabetes and the control subjects;
however, the vasodilatory effect of adenosine and ATP and the sympatholytic effect of ATP seem
to decline with age.
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n healthy people, blood ﬂow regula-
tion during exercise is well matched to
metabolic demands; vasodilation oc-
cursinactivemuscles,broughtaboutbya
complex interaction of various factors
regulating the vascular tone in the micro-
circulation.One suchfactor istoovercome
thesympatheticallymediatedvasoconstric-
tion. Direct recordings of muscle sympa-
thetic nerve activity (MSNA) show that
exercise-induced increase in sympathetic
discharge is targeted to both inactive and
activeskeletalmuscles(1).Inthelatter,this
vasoconstrictor activity is opposed by an
inhibition termed “functional sympatho-
lysis” (2).
Prostaglandins do not seem to be
mandatory for functional sympatholysis,
and exogenous nitric oxide cannot op-
pose sympathetic vasoconstriction (3).
Combined inhibition of nitric oxide and
prostaglandins augments sympathetic
a-adrenergic vasoconstriction, yet the va-
soconstrictor responses were substan-
tially blunted compared with resting
conditions, indicating that other signals
compensate to maintain blood ﬂow to
the contracting muscle (4).
ATP and adenosine are present in
both the systemic circulation and the
microcirculation and may be part of car-
diovascular regulation because of a direct
vasodilatory effect on purinergic endo-
thelial receptors (5). Circulating ATP, but
not adenosine, was demonstrated to
cause a concomitant vasodilation and in-
hibition of sympathetic vasoconstriction,
indicatinganinvolvementofATPinfunc-
tional sympatholysis (6). These versatile
actions of ATP on vascular tone may
therefore have clinical implications for
thepathogenesisofhypertensionandath-
erosclerosis and in the reduced exercise
capacity observed in patients with diabe-
tes (7), in whom the ability to increase
leg blood ﬂow (LBF) during exercise
may be attenuated (8) and the vasocon-
strictor responsiveness, as reﬂected in
MSNA, is increased (9).
We have recently demonstrated that
the vasodilatory effect of the purinergic
system is attenuated in patients with type
2 diabetes (10). The current study fo-
cused on the capacity of functional sym-
patholysis in skeletal muscles during
moderate exercise in patients with type
2 diabetes. The patients were selected to
have a preserved endothelial function,
based on their response to infusions
with acetylcholine. Moreover, we evalu-
ated the capacity of ATP as a sympatho-
lytic agent and the vasodilatory potency
of infusions of ATP and adenosine.
RESEARCH DESIGN AND
METHODS—Ten subjects with type 2
diabetes and 10 age-matched healthy
control subjects participated, all fully in-
formed of the risks and discomforts asso-
ciated with the experiments. The Ethics
Committee for the Copenhagen County
approved the study.
Patients were recruited from Steno
Diabetes Center, an outpatient clinic spe-
cialized in treating patients with a history
of poor glucose control or diabetes com-
plications; subject characteristics are pro-
vided in Table 1. The patients continued
their usual medication because anti-
diabetic, antihypertensive, and lipid-
lowering drugs exhibit long-term effects
without acute affection of cardiovascular
regulation. Only insulin (four partici-
pants) was stopped on the day of the
study. Patients with nephropathy or
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Pathophysiology/Complications
ORIGINAL ARTICLEhistory of angina, acute myocardial in-
farction, or claudication were excluded.
A sam a r k e ro fm u s c l ee n d o t h e l i a l
function, the elevation in LBF during
acetylcholine infusion was evaluated. All
10 subjects had an increase in LBF within
the normal range (Fig. 1).
Control subjects were recruited
through advertising in local newspapers,
had no history of impaired glucose toler-
ance, and received no medications.
On the day of the experiment, partic-
ipantsreportedtothelaboratoryat8:00 A.M.
after a light breakfast. BMI and leg mass
were calculated from whole-body dual–
energy X-ray absorptiometry scanning (GE
Medical Systems, Fairﬁeld, CT). With the
participant resting in a supine position,
three catheters were placed under local an-
esthesiainthefemoralarteryandveinofthe
right leg and inthe femoral artery ofthe left
legusingtheSeldingertechnique.Catheters
were inserted 2 to 3 cm distal from the in-
guinal ligament.
The participants underwent the fol-
lowing protocol: a pretest in which the
individual target LBF was determined
during ;2 min of knee-extensor exercise
at 15 W (11). LBF was increased in a dose-
response manner by infusion of adenosine
or ATP until LBF matched that obtained
during the pre-exercise test. Adenosine
(18.7 mmol/mL; Item Development AB,
Stockholm, Sweden) was infused at rates
of ;0.8 in control subjects and ;1.1
mmol/min in patients (P =0 . 3 8 ) ,w h e r e a s
ATP (1 mmol/mL, Sigma A7699; Sigma-
Aldrich Co., St. Louis, MO) was infused
at rates of ;0.8 and ;0.9 mmol/min in
control subjects and patients (P = 0.62),
respectively, to increase blood ﬂow to tar-
get LBF (;2.8 L/min). This amount of in-
fused ATP, sufﬁcient to increase plasma
content by an estimated 500 nmol, is
within physiologic range (12).
The vasoconstrictor effect of tyra-
mine (5.9 mmol/mL, Sigma T-2879;
Sigma-AldrichCo.),whichevokesendog-
enous noradrenaline (NA) release from
sympathetic nerve endings and sub-
sequent postjunctional a-adrenergic va-
soconstriction, was examined during
adenosine (control), ATP, and exercise-
induced hyperemia; the latter two were
randomized (13). Tyramine was coin-
fused during adenosine at rates of ;5.4
and ;7.4 mmol/min in control subjects
and patients, respectively (P = 0.12), to
reduce LBF by ;50% without affecting
arterialbloodpressure(6).Theindividual
infusion rate of tyramine, resulting in
50% reduction of LBF during adenosine,
was used in the following tyramine trials.
LBF was calculated from measure-
ments of diameter and blood velocity
using the Doppler ultrasound method:
p r o b e8 C( V i v i d7 ;G EH e a l t h c a r e ,L i t t l e
Chalfont,Buckinghamshire,U.K.)(10,14).
LBF represents the average of three mea-
surements obtained atbaseline,4 minafter
thestartofexercise,or4minafterreaching
steady state under infusion of ATP, adeno-
sine, or coinfusion of tyramine.
Pressure transducers (Pressure Mon-
itoring Kit; Baxter, Deerﬁeld, IL) moni-
tored mean arterial pressure (MAP); heart
rate was determined from an electrocar-
diogram, with all data continuously
recorded using a Powerlab system
(ADInstruments, Sydney, Australia).
Statistical analyses were performed
with SigmaPlot 11. Difference of baseline
values and subject characteristics was
tested using a Student t test. D-values of
all hemodynamic variables were calcu-
lated as the difference between baselines
immediately before the intervention and
steady state during the intervention and
analyzed by two-way ANOVA repeated
measurements with nucleotides as within-
subject factors and control/type 2 dia-
betes as between-subject factors. The
Student-Newman-Keuls method was
used to correct for multiple compari-
sons. Signiﬁcance level was set at P ,
0.05. Data are presented as mean 6 SE
unless otherwise stated.
RESULTS
Hemodynamic variables
Thevasodilatory potency ofadenosineand
ATP was similar in control subjects and
patients(309654vs.250681mL/mmol
ATPzkg [P = 0.48] and 13.3 6 1.7 vs.
12.5 6 4m L / mmol adenosinezkg [P =
0.38]).
During adenosine and ATP infusions,
LBF increased ninefold in both control
subjects and patients to similar levels as
during the exercise intervention (2.7 6
0.2 L/min, Fig. 1). In both groups, tyra-
mine infusion reduced LBF during coin-
fusion with adenosine from 2.6 6 0.2 to
1.4 6 0.1 L/min, whereas infusion of the
same amount of tyramine during exercise
didnotreduceLBFineithergroup(2.66
0.25 L/min).
Coinfusion with tyramine during
ATP infusion reduced LBF (from 2.9 6
0.2 to2.0 6 0.2 L/min in control subjects
and from 2.7 6 0.3 to 2.2 6 0.2 L/min in
patients; P =0 . 5 5f o rc o n t r o ls u b j e c t sv s .
patients) (Fig. 1).
Leg vascular conductance (LVC) in-
creased similarly from baseline values of
3 6 0.4 to 27 6 2 mL/minzmmHg during
adenosine and 30 6 4m L / m i n zmmHg
Table 1—Demographic data for diabetic subjects (n = 10) and control subjects (n = 10)
Control subjects Diabetic subjects
Male/female 6/4 6/4
Age (years) 55 6 25 5 6 2
Height (m) 1.76 6 0.02 1.74 6 0.03
Weight (kg) 83.2 6 3 88.9 6 5
BMI (kg/m
2) 26.5 6 1.0 29.1 6 1.4
Leg total mass (kg) 14.5 6 0.8 15.2 6 0.4
Leg muscle mass (kg) 9.9 6 0.6 10.2 6 0.6
P-glucose (mmol/L) 5.9 6 0.2 10 6 1*
C-peptide (pmol/L) 1,230 6 283
HbA1c (%) 5.4 6 0.2 7.6 6 1.2*
Range 5.2–5.7 5.4–8.8
Duration of diabetes (years) 6
Range (years) 2–13
P-cholesterol (mmol/L) 5.8 6 0.8 3.9 6 0.6
P-HDL (mmol/L) 1.4 6 0.4 1.1 6 0.5
P-LDL (mmol/L) 3.6 6 0.9 1.9 6 1.1
P-triglycerides (mmol/L) 1.7 6 0.9 3.2 6 1.6
Data are presentedas means 6SE,with theexceptionof years of diabetes(median value).P-glucose sampled
at the beginning of the ﬁrst intervention because study participants were not fasting. All participants with
diabetes were treated with lipid-lowering medication; one participant was only treated with sulfonyl, nine
participants were treated with metformin (in combination with sulfonyl in four of these). All male patients
receivedantihypertensivetreatmentwithACEinhibitorsorAT-IIantagonist(incombinationwiththiazidein
three of these and with addition of Ca-antagonist in one of these). None of the control subjects received
medication. *P , 0.001.
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Thaning and Associatesduring ATP and decreased similarly dur-
ingcoinfusionoftyramine(1262during
adenosine and 22 6 3m L / m i n zmmHg
duringATP).Duringexercise,LVCincreased
in both groups to 21 6 4m L / m i n zmmHg
and was not affected by tyramine coin-
fusion.
MAPatbaselinewas slightly higher in
the control group, yet not signiﬁcant and
potentially reﬂecting antihypertensive
treatment in the group with diabetes.
MAP increased from baseline (101 6 4
in control subjects vs. 94 6 4m m H gi n
patients)tosimilarvaluesduringexercise,
120 6 4 mmHg in both groups. During
adenosine infusion, MAP was unaltered,
but during coinfusion with tyramine,
MAP increased in both groups to 107 6
3 mmHg. ATP infusion lowered MAP to
94 6 3 in control subjects and 86 6 4
mmHg in patients. Although coinfusion
of ATP and tyramine did not affect MAP
in control subjects (95 6 4m m H g ) ,M A P
increased (to 94 6 4 mmHg) in patients
(P , 0.05).
The arteriovenous differences of O2
content did not differ at baseline (92 6
7 in control subjects vs. 77 6 9m L / Li n
patients, P = 0.24) or during the different
interventions. During exercise, the arte-
riovenous difference increased similarly
(130 6 6 mL/L) and coinfusion with ty-
ramine did not alter the values. Reﬂecting
the alterations in LBF, with combined in-
fusion of adenosine and tyramine, leg ar-
teriovenous O2 difference increased from
11 6 2 mL/L with adenosine infusion to
19 6 3 mL/L with combined adenosine
and tyramine and from 14 6 3t o1 86 4
mL/L during ATP and ATP-tyramine in-
fusion, respectively, with no differences
in the groups.
O2 delivery was proportional to LBF,
andasmalldifferenceinbaselineLBFwas
reﬂec t edi nab a se li n ed i f f e re nc eo fO 2 de-
livery (P = 0.14). However, there were no
differences in O2 delivery or uptake dur-
ing the infusions of adenosine, ATP, ex-
ercise, or coinfusion of tyramine.
Heart rate at baseline tended to be
higher in patients (68 6 4 in control sub-
jectsvs.7964bpminpatients,P=0.06),
but during the interventions, d values
were similar. In addition, cardiac output
differed at baseline (4.0 6 0.4 in control
subjects vs. 6.0 6 0.5 L/min in patients,
P = 0.005), but during ATP infusion and
exercise, d values were similar. In con-
trast, cardiac output increased more in
the group with diabetes during adenosine
infusion, both with and without tyra-
mine, P = 0.03 (control subjects vs. pa-
tients, both adenosine and coinfusion of
adenosine and tyramine).
Venous NA
At baseline, femoral venous NA was
different (2.6 6 0.2 in control subjects
vs. 1.8 6 0.2 nmol/L in patients, P =
0.001),butNAincreasedsimilarlyduring
exercise(1.360.5nmol/L,P=0.98,Fig.2).
The increases during tyramine coinfusion
also were similar in the two groups (2.2 6
0.4 for adenosine, 1.5 6 0.3 for ATP, and
3.2 6 0.5 nmol/L during exercise P = 0.4
to0.6),asweretheincreasesinvenousNA
adjusted for the individual infusion rates
of tyramine (0.38 6 0.08 during adeno-
sine infusion, 0.25 6 0.04 during ATP in-
fusion, and 0.56 6 0.11 nmol/L during
exercise per micromole oftyramine).Dur-
ing adenosine infusions, venous NA did
.
Figure 1—LBF, LVC, and MAP at baseline and during all hyperemic interventions. There were
no signiﬁcant differences between the groups at baseline or during the interventions. ACh, ace-
tylcholine; ADO, adenosine; DM, diabetes mellitus; EX, exercise; tyr, tyramine. *Different from
the previous intervention. †Different from ADO-tyr.
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Functional sympatholysis in patients with diabetesnot change in the two groups, whereas
during ATP infusion, NA increased in
the control group (P = 0.003). This differ-
ence was also reﬂected during combined
ATPandtyramineinfusions,wherevenous
NA in the group with diabetes tended
to be lower compared with adenosine
(P = 0.053).
During combined adenosine and ty-
ramine infusion, the ﬂow reduction per
micromole of tyramine was similar in the
two groups (245 6 40 mL/mmol tyra-
mine), whereas during ATP infusion, the
sensitivity to tyramine in terms of ﬂow
reduction was lower in the group with di-
abetes (182 6 27 vs. 92 6 34 mL/mmol
tyramine, P =0 . 0 4 2 ) .
CONCLUSIONS—The main ﬁndings
of the current study are that patients with
type 2 diabetes and intact endothelial
function have a similar capacity to blunt
sympathetic vasoconstriction during
moderate exercise as healthy age- and
BMI-matched control subjects. However,
bothgroupswereonlypartiallycapableof
blunting a-adrenergic vasoconstriction
during ATP-induced hyperemia. In addi-
tion, the vasodilatory potency of adeno-
sine and ATP did not differ between
patients and control subjects. Finally, the
subjects with diabetes had a lower venous
content of NA but a similar elevation of
venousNAduringtheadenosineinfusions,
exercise, and tyramine interventions.
Functional sympatholysis and
sympatholytic effect of ATP
Consistent witha studyonyoung healthy
subjects (6), exercise fully blunted sym-
pathetic vasoconstriction in both groups,
indicating that the ability of functional
sympatholysis during moderate exercise
was not reduced in the group with diabe-
tes. This may be clinically relevant given
that pathology, affecting the vasodilatory
function, could be expected to limit skel-
etal muscle blood ﬂow because of en-
hanced sympathetic vasoconstriction in
the active muscles, thereby potentially re-
ducing exercise capacity.
A study on elderly healthy humans
(.65 years) demonstrated that aging is
associated with a greater vasoconstrictor
tone in active muscles during exercise
compared with young adults (15). The
magnitude of functional sympatholysis
was signiﬁcantly lower in older persons
compared with young persons in the
presence of tyramine, leading the authors
to conclude that aging is associated with
impaired functional sympatholysis in the
vascularbedsofcontractingforearmmus-
cle. The present ﬁnding of intact func-
tional sympatholysis in middle-aged
healthy subjects and patients with diabe-
tes could demonstrate that the phenome-
non may be age-dependent; however,
limb differences should also be kept in
mind (16). Moreover, a component of
systemic limitation to peripheral blood
ﬂow during exercise may explain the ob-
served low blood ﬂows in some studies of
patients with type 2 diabetes; the knee-
extensor model eliminates this risk and
therefore allows studies of the local mi-
crocirculation and may not be translated
to all skeletal muscles or applied to high-
intensity exercise with a large muscle
massbutislikelytorepresentthelegmus-
cles,whichaccounts forthelargestpartof
vascular resistance in the body and is of
particular interest because insulin resis-
tance is primarily present in leg muscles
(17).
In young subjects, luminal ATP was
shown to abolish tyramine-induced sym-
pathetic vasoconstriction, indicating that
ATP is contributing to functional sympa-
tholysisviaactivationoftheP2Y2receptor
(6). In contrast with this ﬁnding, both
groups in the current study had a reduc-
tion in LBF during combined ATP and
tyramine infusion. The sympatholytic ef-
fect of ATP is graded and dose-dependent;
during very modest ATP infusions, ATP
had no sympatholytic effect (18). How-
ever, the present infusion rates of ATP
increased LBF ninefold, most likely in-
creasing arterial ATP to levels sufﬁcient to
limit a-adrenergic vasoconstriction in
young subjects. Therefore, the sympatho-
lytic effect of ATP may be affected by age.
In contrast with ATP, adenosine has
minor sympatholytic effect (6,13). The
amount of tyramine leading to 50%
reduction in LVC and LBF during aden-
o s i n ei n f u s i o nr e s u l t e di na;30% re-
duction during ATP; thus, ATP has a
role in functional sympatholysis in the
elderly, but other factors must be of im-
portance to offset sympathetic vasocon-
striction,becausetherewerenochanges
in LVC or LBF during exercise with co-
infusion of tyramine. Functional sym-
patholysis in middle-aged persons
could gradually be more dependent on
factors other than ATP, such as KATP
channel activation, which opposes
a-adrenergic vasoconstriction during
muscle contraction (19).
Regardless of the compounds re-
sponsible for functional sympatholysis,
endothelial function also could be of
importance. The presentﬁndings do not
exclude that endothelial dysfunction
affects the ability of sympatholysis dur-
ing exercise.
Vasodilatory action of adenosine
and ATP
The amount of ATP and adenosine
needed to increase LBF tolevelsmatching
exercise was similar in the two groups. In
contrast, in a previous study on patients
with diabetes and age-matched control
subjects,wefounda50%reductioninthe
LBFresponsetoATPandadenosineinthe
group with diabetes (10). The LBF re-
sponse in control groups was identical,
whereastheresponseinthepresentgroup
withdiabeteswashigherinregardtoboth
ATPandadenosine.Whencomparingthe
two groups of patients with diabetes,
there were no differences in demographic
variables or medication. Only the LBF re-
sponse to acetylcholine infusion was
Figure 2—Venous NA at rest and during hy-
peremia. A: Adenosine. B:A T P .C:E x e r c i s e .
*Different from control. †Different from the
previous intervention.
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Thaning and Associatessigniﬁcantly different, indicating that the
reduction in effect of purinergic agonist
may be proportional to the extent of en-
dothelial dysfunction.
A comparison of data from our two
studies of middle-aged subjects, both
control subjects and patients with diabe-
tes, and previous studies of young sub-
jects (20,21) demonstrates a decline in
LBF response to adenosine in particular,
which was reduced fourfold. In regard to
ATP, there was a clear decline in sensitiv-
ityonlyinthegroupwithmoredeveloped
endothelial dysfunction. Still, it is a pos-
sibility that the response to ATP also is
diminished in an elderly population, pos-
sibly to a minor extent, because the dose-
response in young healthy subjects may
not be linear for the dose interval under
study, hampering data extrapolation and
direct comparison (6).The decline in LBF
responses to ATP and adenosine may re-
ﬂect age-related changes of the signaling
pathways (20,21). However, physical in-
activity and obesity also affect endothelial
function and cardiovascular regulation
and should be of note, because both
groups in the current study had moder-
ately elevated BMI and the majority of the
subjects had a sedentary lifestyle.
Venous NA and sensitivity
The interpretation of plasma levels of NA
and its correlation to sympathetic activity
is complex; plasma NA elevation may not
be a precise measure of the effect on
MSNAbutmerelyareﬂectionofdirection
of change. It should be noted that during
infusion with adenosine alone, there was
no increase in venous NA, despite a nine-
fold increase in LBF, indicating that the
increase in NA was indeed due to tyra-
mine infusion and not to hyperemia.
D-values of venous NA between the
two groups were similar during all three
tyramine interventions. Furthermore,
during moderate exercise, both with and
withouttyramine,thevenousNAincrease
in the groups was similar and additive,
indicating that the stimulus of exercise
to the sympathetic system also may have
been uniform. These ﬁndings are consis-
tent with previous studies in young sub-
jects, showing that NA spillover is a
function of active muscle mass and exer-
cise intensity (22).
In young subjects (6), plasma NA in-
creased from ;1.7 nmol L
21 at baseline
to ;3n m o lL
21 during tyramine infu-
sions with comparable infusion rates,
thus lower than in the present middle-
agedcontrolsubjects.However,thelevels
of NA in the present group of patients
with diabetes were similar to those of
young subjects.
Despite increases in sympathetic
nerve activity in patients with diabetes,
plasma NA level has been found to be
reduced compared with control subjects
(23). Therefore, it is of interest to investi-
gate whether the presented differences
are a result of antidiabetic treatment or a
physiologic response to elevation in sym-
pathetic nerve activity, leading to en-
hanced reuptake and thus a reduced
spillover.
Circulating ATP mimics exercise hy-
peremia by its vasodilatory potency and
by increasing MSNA and circulating NA
(6). Measurements of interstitial NA in
skeletal muscle during ATP infusion
with the microdialysis technique showed a
dose-dependent increase in interstitial NA,
whereas interstitial NA increased to a larger
extent during exercise, despite similar
LBF, consistent with the results in the
present control group (24). The lack of
increase in venous NA during ATP infu-
sion in the group with diabetes may be to
the result of an impaired baroreceptor
function (25) or altered function of the
ATP inducement of NA exocytosis be-
cause the changes in MAP during ATP in-
fusions were similar in the two groups.
D-values of venous NA during tyra-
mine infusion and the changes in LVC
were proportional and similar in the two
groups, suggesting that the subjects with
diabetes were equally sensitive to NA
as the control subjects. Therefore, the
present measurements of venous NA may
reﬂect interstitial conditions, and the pre-
served functional sympatholysis in the
group with diabetes could be partly attrib-
uted to a reduced level of NA, perhaps in
combination with or attributed to a reduc-
tion in ATP-induced sympathetic activity.
Limitations
The primary limitation is that no truly
selective human antagonists and ligands
of P2 receptors are currently available,
whichhindersconﬁrmatorystudiesofthe
role of the purinergic system.
Power calculations ahead were im-
peded because the current study is the
ﬁrst to investigate this particular area in
patients with diabetes. In our previous
study on 10 control subjects and 10
patients with diabetes and endothelial
dysfunction, we demonstrated clear and
signiﬁcant differences in the relevant var-
iables(10).However,patientswithtype2
diabetes are a heterogenic group, and
sample size for the current study does
notnecessarilyreﬂectsuchheterogeneity.
Antidiabetic and antihypertensive
treatment has been shown to improve
endothelial function through several
pathways, and studies of patients with
diabetes have been carried out primarily
during withdrawal of medications; how-
ever, in most studies analyzing risk pro-
ﬁles of different chronic diseases, the
patients are usually taking medication. It
may be more accurate to investigate pa-
tientsintheir“normal”functionalstatusif
the drugs do not affect the measurements
directly, because little is known of the
time course after withdrawal.
CONCLUSIONS—Patients with well-
diagnosedtype 2diabetes andonlyminor
or no endothelial affection have an intact
capacity of functional sympatholysis dur-
ing moderate exercise. However,both the
patients and the aging control subjects
have a lower sympatholytic effect of ATP.
Because this does not compromise func-
tional sympatholysis, ATP is not manda-
tory for an adequate hyperemic response
during exercise.
The LBF response to ATP and aden-
osine was similar in the two groups; thus,
purinergic-induced LBF may not be af-
fected by diabetes per se; attenuation of
purinergic vasodilation in patients with
diabetes could be a result of endothelial
dysfunction.
When comparing the present ﬁndings
with those of young subjects, the vaso-
dilatory potency of adenosine in particular
may be markedly reduced by aging and
further aggravated with diabetes, in corre-
lation to the grade of endothelial affection.
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